Neurophysiological markers of motor reserve in Parkinson’s disease
Objective: Our objective was to investigate Motor Reserve (MR) in idiopathic Parkinson’s Disease (PD). Background: MR is defined as the resilience mechanisms of the brain…Pilot study of outpatient rehabilitation of patients with Huntington’s disease in Russia
Objective: The benefits of exercises and physical activity in Huntington's disease in terms of motor function, gait speed, and balance, as well as a range…Dysphagia in Parkinson’s disease
Objective: To evaluate the presence of dysphagia in patients with Parkinson Disease (PD) and determine associated factors and possible clinical predictors. Background: Parkinson's disease (PD)…Can a global measure of cognition be used to inform balance interventions in Parkinson’s disease?
Objective: To examine the relationship between domains of cognition, using the Montreal Cognitive Assessment (MoCA), and domains of balance, using the Mini Balance Evaluation Systems…A network imaging biomarker of X-linked dystonia-parkinsonism
Objective: To characterize a metabolic brain network associated with X-linked dystonia-parkinsonism (XDP). Background: X-linked dystonia-parkinsonism (XDP, DYT/PARK-TAF1, Lubag) is an X-linked recessive movement disorder characterized…A rare case of PDE10A associated dystonia with bilateral striatal lesions
Objective: To describe an interesting and rare case of cervical dystonia associated with PDE10A mutation. Background: Dystonia is the third most prevalent movement disorder in…Gene-environment interactions for Parkinson’s disease
Objective: The aim of this study was to test for interactions between PD-related genetic and phenotypic traits in the 23andMe, Inc. research cohort. Background: Parkinson’s…Study protocol for the iMarkHD study in individuals with Huntington’s disease
Objective: To describe the study protocol for the iMarkHD study. Background: Huntington’s disease (HD) is still often defined by the onset of motor symptoms, inversely…Integrated safety analysis of BIA-28-6156 phase 1 clinical trials (a novel allosteric activator of beta-glucocerebrosidase)
Objective: To describe the safety profile and tolerability of BIA-28-6156 observed during phase 1 clinical trials. Background: BIA-28-6156 is a novel allosteric activator of beta-glucocerebrosidase…Microelectrode recording with subthalamic nuclei deep brain stimulation encompass neuro-electro physiological beta oscillations footmarks in Parkinson`s cardinal motor symptoms sub-types
Objective: To examine the behavioral-activity within sub bands of β-beta-oscillated local field potentials(‘LFP’) acquired through microelectrode recording(MER) from STN sub areas offer distinctive neuro-electro physiological…
- « Previous Page
- 1
- …
- 72
- 73
- 74
- 75
- 76
- …
- 186
- Next Page »